Abilify Maintena

DRUG4 trials

Sponsors

Gazda, Thomas D., M.D., PC, Korea Otsuka Pharmaceutical Co., Ltd., Martha Sajatovic, Chonbuk National University Hospital

Conditions

AntipsychoticsAripiprazoleBipolar DisorderLAILong-Acting InjectionMedication AdherenceMedication Non AdherenceSchizophrenia

Phase 4

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

TerminatedNCT02472652

Gazda, Thomas D., M.D., PCSexual Dysfunction

Start: 2015-06-30End: 2017-03-01Updated: 2019-04-11

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

CompletedNCT03376763

Korea Otsuka Pharmaceutical Co., Ltd.Antipsychotics, Aripiprazole, LAI +2

Start: 2017-11-21End: 2021-11-19Updated: 2021-12-17

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

CompletedNCT03408873

Martha SajatovicBipolar Disorder, Medication Adherence, Medication Non Adherence

Start: 2018-04-01End: 2020-05-06Updated: 2022-02-17

Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients

CompletedNCT03839251

Chonbuk National University HospitalSchizophrenia

Start: 2018-06-01End: 2020-09-30Updated: 2021-01-27

Related Papers

Long-Acting Injectable Antipsychotic Medication Plus Customized Adherence Enhancement in Poor Adherence Patients With Bipolar Disorder

The Primary Care Companion For CNS Disorders2021-09-1611 citations